Smead Capital Management Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,557,455 shares of the biopharmaceutical company’s stock after selling 50,217 shares during the quarter. Pfizer accounts for about 3.2% of Smead Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Smead Capital Management Inc.’s holdings in Pfizer were worth $67,469,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. BKD Wealth Advisors LLC raised its stake in shares of Pfizer by 2.5% in the fourth quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock worth $4,553,000 after purchasing an additional 2,561 shares during the last quarter. Joel Isaacson & Co. LLC raised its stake in shares of Pfizer by 71.1% in the fourth quarter. Joel Isaacson & Co. LLC now owns 65,093 shares of the biopharmaceutical company’s stock worth $2,791,000 after purchasing an additional 27,058 shares during the last quarter. PFG Advisors raised its stake in shares of Pfizer by 40.6% in the fourth quarter. PFG Advisors now owns 9,321 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 2,690 shares during the last quarter. Gemmer Asset Management LLC raised its stake in shares of Pfizer by 3.6% in the fourth quarter. Gemmer Asset Management LLC now owns 29,532 shares of the biopharmaceutical company’s stock worth $1,289,000 after purchasing an additional 1,017 shares during the last quarter. Finally, Nachman Norwood & Parrott Inc purchased a new position in shares of Pfizer in the fourth quarter worth about $3,223,000. Hedge funds and other institutional investors own 71.81% of the company’s stock.
Pfizer stock traded down $0.52 during midday trading on Friday, hitting $36.35. 21,609,556 shares of the company were exchanged, compared to its average volume of 30,679,872. The company has a market cap of $204.99 billion, a price-to-earnings ratio of 12.12, a PEG ratio of 2.94 and a beta of 0.63. Pfizer Inc. has a fifty-two week low of $35.86 and a fifty-two week high of $46.47. The stock’s fifty day simple moving average is $42.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.96%. The ex-dividend date is Thursday, August 1st. Pfizer’s payout ratio is currently 48.00%.
In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.
PFE has been the subject of several research analyst reports. JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. Goldman Sachs Group restated a “buy” rating and issued a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Morgan Stanley cut Pfizer from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. UBS Group restated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Finally, Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Fourteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $46.56.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.